CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna
VA
22182
United States

Tel: (703) 506-9460

About CEL-SCI Corporation

CEL-SCI Corporation is a pioneer in cancer immunotherapy. We are a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer, infectious and autoimmune diseases. CEL-SCI believes that boosting a patient's immune system before surgery, radiation and chemotherapy should provide the greatest possible impact on survival since that is the time when the immune system is the strongest. Therefore, in the Phase 3 clinical study CEL-SCI treated patients who were newly diagnosed with head and neck cancer with Multikine immunotherapy right after diagnosis, BEFORE they went on to receive surgery, radiation and/or chemotherapy. This approach is unique since cancer drugs are mostly given after surgery, radiation and chemotherapy have failed. The Phase 3 study is the largest ever in head and neck cancer with 928 patients enrolled. It reached the targeted threshold required to conduct data evaluation and is currently in the statistical analysis phase. Head and neck cancer represents about 6% of all cancers worldwide and an unmet medical need. Multikine has received Orphan Drug designation from the FDA for this indication. CEL-SCI operates its own 73,000 sq. ft. GMP manufacturing facility that produces Multikine and a separate research & development laboratory that supports the manufacturing of Multikine. CEL-SCI has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Stock Symbol: CVM

CEL-SCI Corporation Overview

465 articles with CEL-SCI Corporation

CEL-SCI to Present at the ThinkEquity Conference

4/30/2019

CEL-SCI Corporation announced that Geert Kersten, Chief Executive Officer, will be presenting at the ThinkEquity Conference in New York, NY on Thursday, May 2, 2019 at 1:00 p.m.
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study - March 29, 2019

3/29/2019

CEL-SCI Corporation announced that the Independent Data Monitoring Committee for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* has completed its recent review of the Phase 3 study data.
CEL-SCI Corporation Releases Letter to Shareholders - March 25, 2019

3/25/2019

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting
CEL-SCI Selected by National Institutes of Health to Showcase Its LEAPS Technology at BIO International Convention

3/7/2019

Platform therapeutic vaccine technology to be showcased at NIH’s Innovation Zone
CEL-SCI’s Scientific Article on Vaccines for Autoimmune Disease Published in Journal of Clinical & Cellular Immunology

3/4/2019

LEAPS therapeutic vaccine platform holds potential for early treatment of autoimmune diseases including rheumatoid arthritis, multiple sclerosis and type 1 diabetes
CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results

2/14/2019

CEL-SCI Corporation reported financial results for the quarter ended December 31, 2018.
CEL-SCI to Present at 2019 BIO CEO & Investor Conference

2/7/2019

Geert Kersten, Chief Executive Officer, will be presenting at the 2019 BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2018 at 2:00 p.m.
U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology

1/23/2019

CEL-SCI’s LEAPS inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides
CEL-SCI Regains Full Listing Compliance with NYSE American

1/15/2019

The Company is now considered in full compliance with the continued listing requirements.
CEL-SCI Reports Fiscal 2018 Financial Results and Clinical & Corporate Developments

12/20/2018

CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2018
CEL-SCI Announces Warrants to Expire on October 11, 2018

9/28/2018

CEL-SCI Corporation is advising the holders of its publicly traded warrants (NYSE American: CVM WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 11, 2018.
NIH Selects CEL-SCI’s LEAPS Rheumatoid Arthritis Vaccine for Commercialization Accelerator Program

9/5/2018

CEL-SCI Corporation announced today that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine candidate as a Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Commercialization Accelerator Program Phase II awardee for 2018-2019.
CEL-SCI Corporation Releases Letter to Shareholders

8/21/2018

The following letter was sent by CEL-SCI Corporation to its shareholders for the upcoming annual meeting
CEL-SCI Announces That the NYSE American Approves Plan

8/17/2018

CEL-SCI Corporation announces that the NYSE American (the “Exchange”) has accepted the Company’s plan to bring itself into compliance with the Exchange's continued listing standards.
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

8/15/2018

CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data.
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2018 Financial Results

8/14/2018

CEL-SCI Corporation reported financial results for the quarter ended June 30, 2018. The Company also reported key clinical and corporate developments achieved during the quarter.
CEL-SCI Reports on NYSE American Noncompliance Notice and Compliance Plan

7/13/2018

CEL-SCI Corporation reported on a communication received today from the staff of the NYSE American, its current listing exchange, that it considered the Company to be noncompliant with certain listing requirements based on its quarterly report for the period ended March 31, 2018.
CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering and Concurrent Private Placement

7/2/2018

CEL-SCI Corporation announced that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors.
Cel-Sci Wins Breach of Contract Ruling against Clinical Research Organization inVentiv, Now Known as Syneos Health

6/27/2018

CEL-SCI Corporation (NYSE American: CVM) announced today that after a four and a half year battle a decision has been delivered by the arbitrator in CEL-SCI's arbitration suit against clinical development giant inVentiv.
CEL-SCI Corporation Issues Letter to Shareholders

6/11/2018

CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.